Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies

J Zhang, Y Zhang, J Wang, Y **a, J Zhang… - Signal transduction and …, 2024 - nature.com
Alzheimer's disease (AD) stands as the predominant form of dementia, presenting significant
and escalating global challenges. Its etiology is intricate and diverse, stemming from a …

Challenges and hopes for Alzheimer's disease

SA Tatulian - Drug discovery today, 2022 - Elsevier
Recent drug development efforts targeting Alzheimer's disease (AD) have failed to produce
effective disease-modifying agents for many reasons, including the substantial …

Alzheimer's disease: Recent treatment strategies

M Vaz, S Silvestre - European journal of pharmacology, 2020 - Elsevier
Alzheimer Disease (AD) is a neurodegenerative disease characterized by two
neuropathological hallmarks: extracellular deposition of amyloid plaques and intracellular …

Current and future treatments in Alzheimer disease: an update

KG Yiannopoulou… - Journal of central …, 2020 - journals.sagepub.com
Disease-modifying treatment strategies for Alzheimer disease (AD) are still under extensive
research. Nowadays, only symptomatic treatments exist for this disease, all trying to …

History and progress of hypotheses and clinical trials for Alzheimer's disease

PP Liu, Y **e, XY Meng, JS Kang - Signal transduction and targeted …, 2019 - nature.com
Alzheimer's disease (AD) is a neurodegenerative disease characterized by progressive
memory loss along with neuropsychiatric symptoms and a decline in activities of daily life. Its …

Tau-targeting therapies for Alzheimer disease: current status and future directions

EE Congdon, C Ji, AM Tetlow, Y Jiang… - Nature Reviews …, 2023 - nature.com
Alzheimer disease (AD) is the most common cause of dementia in older individuals. AD is
characterized pathologically by amyloid-β (Aβ) plaques and tau neurofibrillary tangles in the …

Recent advances on drug development and emerging therapeutic agents for Alzheimer's disease

T Athar, K Al Balushi, SA Khan - Molecular biology reports, 2021 - Springer
Alzheimer's disease (AD) is a neurodegenerative old age disease that is complex,
multifactorial, unalterable, and progressive in nature. The currently approved therapy …

The amyloid-β oligomer hypothesis: beginning of the third decade

EN Cline, MA Bicca, KL Viola… - Journal of Alzheimer's …, 2018 - content.iospress.com
The amyloid-β oligomer (AβO) hypothesis was introduced in 1998. It proposed that the brain
damage leading to Alzheimer's disease (AD) was instigated by soluble, ligand-like AβOs …

Development of multifunctional molecules as potential therapeutic candidates for Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis in the …

MG Savelieff, G Nam, J Kang, HJ Lee, M Lee… - Chemical …, 2018 - ACS Publications
Neurodegenerative diseases pose a substantial socioeconomic burden on society.
Unfortunately, the aging world population and lack of effective cures foreshadow a negative …

Activation of microglia and astrocytes: a roadway to neuroinflammation and Alzheimer's disease

D Kaur, V Sharma, R Deshmukh - Inflammopharmacology, 2019 - Springer
Alzheimer's disease (AD) is a neurodegenerative disease that is of high importance to the
neuroscience world, yet the complex pathogenicity is not fully understood. Inflammation is …